Eleven transactions crossed the tape last week, representing roughly $2.11 billion of announced capacity across eleven sectors. The range ran from a $1.1 billion syndicated refinancing for a listed hardware platform to a $1 million factoring line for a staffing firm.
Read the week by size and it looks like a normal summer stretch. Read it by structure and something more interesting emerges. In almost every deal, the borrower did not simply pick the cheapest money. It picked the structure that matched the asset, and the structure then determined which lender could actually write the cheque.
That distinction matters for anyone allocating to asset-based finance. Cash flow lenders, ABL desks, specialty finance firms and life sciences credit funds were all active in the same five days, and they were rarely competing for the same paper.
One caveat worth stating before the detail. Almost every headline number last week is announced capacity rather than funded balance. Kestra’s $200 million facility had $75 million drawn at closing. Hillman’s $375 million ABL revolver sits at zero. Evolve’s $75 million is a $50 million commitment plus a $25 million accordion. Anyone building a market view from press releases is measuring commitments, not exposure.
Hillman Solutions: $1.1 billion across a Term Loan B and an ABL revolver
Hillman Solutions Corp. (Nasdaq: HLMN) closed a refinancing of its existing facilities on 22 July, made up of a $735 million senior secured Term Loan B and a $375 million asset-based revolving credit facility. Jefferies Finance acted as administrative agent on the term loan. U.S. Bank acted as lead arranger and administrative agent on the ABL, with Bank of America, PNC and Fifth Third as joint lead arrangers and First Financial Bank participating.
The term loan matures in July 2033 and prices at SOFR plus 200 basis points. The revolver matures in July 2031 at SOFR plus 125 to 150 basis points, is currently undrawn, and splits into $325 million for the US borrower and $50 million for the Canadian borrower, each subject to a borrowing base.
Why it matters:
This is the clearest example of the week’s theme. One borrower, two facilities, two entirely different underwriting logics. The term loan is priced off enterprise value and leverage. The revolver is priced off eligible receivables and inventory, at 75 basis points inside the term loan, and costs almost nothing while it stays undrawn.
Pricing on both facilities was consistent with the previous credit agreements, which tells you the market repriced maturity risk rather than credit risk. Extending a 2033 term loan and a 2031 revolver at flat spreads is a strong outcome in a market where many issuers are paying up for duration.
Key risks:
The borrowing base is now a live operational dependency in two currencies and two jurisdictions. Eligibility rules, reserves and dilution assumptions apply differently to the US and Canadian pools, and the availability calculation has to be reproducible on demand.
Beyond that, watch inventory eligibility through a retail demand cycle, given Hillman’s exposure to home improvement and hardware retailers. Intercreditor mechanics between the term and revolving lenders also matter, since the collateral packages overlap and the priority split has to hold under stress.
Opportunities:
For ABL lenders, an undrawn $375 million commitment from an investment-grade-style syndicate is annuity income with modest capital intensity. For the borrower, dual-tranche structures create genuine optionality, because working capital swings can be absorbed by the revolver without touching the term loan covenant package.
For asset managers, the broader opportunity is the unbundling itself. Every large sponsor-backed or listed issuer that separates cash flow debt from collateral debt creates a second, separately monitored exposure that needs its own data infrastructure.
Strata Clean Energy: $450 million revolving and letter of credit facility
Strata Clean Energy upsized its revolving loan and letter of credit facility by $150 million, taking it from $300 million to $450 million. The upsize closed on 9 July and was announced on 22 July. Nomura Securities International acted as sole bookrunner and coordinating lead arranger, the same role it held on the original $300 million facility in November 2023, with First Citizens Bank as coordinating lead arranger.
Proceeds support the development, construction and operation of Strata’s renewable energy and storage projects, plus working capital for its engineering and operations divisions.
Why it matters:
Clean energy platforms have historically raised project-level debt against individual assets. This is corporate-level revolving capacity with a letter of credit line attached, which is a very different instrument. It funds the pipeline rather than a single project, and it puts the lender’s exposure against a rotating set of development-stage assets.
The repeat mandate is the second signal. The 2023 arranger came back to lead the upsize, which says as much about information advantage as it does about spread. Lenders who already hold the data on a platform can underwrite an expansion faster than a newcomer can diligence it.
Key risks:
Construction and interconnection timelines dominate. Letter of credit utilisation rises with posted obligations, so the facility’s effective availability moves with commercial activity rather than with the calendar. Policy and tax credit dependencies remain a live variable for US renewables, and concentration by technology vintage and geography can build quietly inside a development pipeline.
Opportunities:
Infrastructure and power finance desks with the capability to monitor a moving pipeline can hold a position that pure project lenders cannot reach. For credit funds, the interesting adjacency is the letter of credit component, which is fee income against contingent exposure and is increasingly a place where non-bank capital can participate.
Kestra Medical Technologies: up to $200 million of non-dilutive term debt
Kestra Medical Technologies (Nasdaq: KMTS), a wearable cardiac device and digital health company, entered a five-year senior secured term loan facility of up to $200 million with funds managed by Pharmakon Advisors, investment manager of the BioPharma Credit funds. The deal was announced on 14 July and appeared on the ABL Advisor tape on 20 July.
The structure runs in four parts. A $75 million tranche funded at closing and retired an existing $45 million term loan. A $25 million tranche is available at the company’s option through July 2027. A further $50 million is available through June 2028, conditional on the company generating $150 million of trailing twelve-month revenue. A final $50 million uncommitted tranche is reserved for acquisitions, subject to lender consent. The facility carries 48 months of interest-only payments, extendable by a further twelve months on a revenue milestone, and prices at three-month SOFR plus 5.50% with a 3.25% floor.
Why it matters:
This is a lender underwriting a commercial ramp, not a balance sheet. Kestra reported fiscal 2026 revenue of $95.1 million, up 59% year on year, and is not yet profitable. Traditional cash flow leverage metrics do not apply.
What Pharmakon has done instead is convert the growth plan into a schedule. Capital is released as revenue milestones are hit, which caps downside if adoption slows and gives the borrower access to size if it does not. For a listed medtech company trading below where it would want to issue equity, that is a materially cheaper form of growth capital than dilution.
Key risks:
Milestone slippage is the obvious one. If trailing revenue does not reach $150 million by June 2028, a third of the facility never arrives, and the funding plan needs a replacement. A minimum liquidity covenant of $20 million sits underneath, and security extends over substantially all assets including intellectual property.
Add single-product concentration and reimbursement policy exposure, and the credit is effectively a bet on one device category’s adoption curve. At SOFR plus 5.50% with a floor, the cost of carry on an unprofitable business is not trivial.
Opportunities:
Milestone-linked, non-dilutive structures are now a genuine competitor to late-stage equity, and the addressable universe extends well beyond biotech into devices, diagnostics and health technology. For specialist credit managers, the barrier to entry is not capital. It is the ability to track revenue, covenant and milestone data at the frequency the structure requires.
Peachtree Group: $150 million hotel portfolio bridge loan
Peachtree Group originated a $150 million bridge loan to refinance a four-hotel, 997-key portfolio in Flamingo Crossings Town Center, adjacent to Walt Disney World Resort in Winter Garden, Florida. The borrower, Doradus Partners, is a repeat client on its fourth transaction with the lender. JLL arranged the deal, which Peachtree closed in fewer than 45 days. It is the largest senior bridge loan in the firm’s history.
The properties were developed in 2020 and 2021 and carry a weighted average occupancy of close to 89%.
Why it matters:
Speed closed this deal, not spread. A sub-45-day execution on a nine-figure hospitality refinancing is something most bank credit committees cannot promise, and the sponsor paid for certainty. That is the private credit value proposition in commercial real estate stated as plainly as it gets.
The repeat borrower dynamic is equally telling. A fourth transaction means the lender already holds performance history, operating data and asset-level familiarity, which compresses diligence and improves pricing confidence on both sides.
Key risks:
Hospitality cash flow is seasonal and demand-sensitive, and this portfolio’s performance is tied to one destination market. Bridge structures carry refinancing risk at maturity, which depends on where permanent debt is available in eighteen to thirty-six months. Concentration is high by location, brand family and sponsor.
Opportunities:
Well-located, recently built assets with strong occupancy are exactly the collateral private credit wants while banks remain selective on hospitality. For managers, the scalable version of this is a repeat-borrower origination model, where relationship data lowers acquisition cost per deal. That only works if asset-level performance data is captured systematically rather than living in a deal team’s inbox.
Bank of Montreal and Evolve Royalties: $75 million secured revolver
Evolve Royalties Ltd. (CSE: EVR) entered a credit agreement with Bank of Montreal for a secured revolving credit facility of $50 million, with an option to increase to $75 million. The facility matures in three years, is secured by a charge over the company’s assets, and can be used for general corporate purposes and to finance acquisitions. Margins range from 1.50% to 2.50% depending on the company’s net leverage ratio.
Why it matters:
A royalty company’s balance sheet is a portfolio of contractual claims on future production. A bank writing a leverage-based revolver against that portfolio is treating royalty streams as a financeable, monitorable asset class rather than as an equity story.
For a small-cap acquirer of base and critical metals royalties, committed revolving capacity is a competitive weapon. It allows the company to close acquisitions without going to the equity market first, which is often the difference between winning and losing a royalty auction.
Key risks:
Royalty income depends on operator performance, commodity prices and mine life, none of which the royalty holder controls. The leverage-based pricing grid means the cost of capital rises exactly when commodity prices fall and leverage climbs. Portfolio concentration in a small number of producing assets amplifies both effects.
Opportunities:
Royalty and streaming finance continues to move towards a recognised specialty credit category, and last week’s transaction sits alongside similar activity in preceding weeks. For lenders, the attraction is contractual cash flow with no operating cost exposure. The requirement is the ability to track production, price and payment data across many operators and jurisdictions on a continuous basis.
MidCap Financial and Keslow Camera: $65 million senior secured facility
MidCap Financial provided a $65 million senior secured credit facility to Keslow Camera, a motion picture and digital cinema camera rental business. Proceeds refinanced existing debt, simplified the capital structure and provided additional liquidity for operations, growth and working capital.
Why it matters:
Cinema equipment is genuinely hard collateral. Cameras, lenses and support gear hold value, have an active secondary market, and can be appraised with reasonable confidence. What makes the asset class demanding is that the collateral moves constantly between productions, locations and countries.
This is the second consecutive week in which cinema equipment financing appeared on the tape, following a facility for another rental platform. Content production capex is being refinanced by specialty lenders while generalist capital stays cautious on media.
Key risks:
Utilisation is the whole credit. Rental fleets earn only when deployed, and production volumes are cyclical and exposed to studio spending decisions. Technology obsolescence sits underneath residual values, and asset tracking across a mobile fleet is an operational challenge, not a theoretical one.
Opportunities:
Lenders who can monitor utilisation, location and appraised value at the individual asset level can lend more comfortably, and more cheaply, than those relying on periodic third-party appraisals. That capability gap is where specialty equipment finance margins actually come from.
Eclipse Business Capital and a frozen food supplier: $55 million ABL facility
Eclipse Business Capital provided a $55 million asset-based lending credit facility to an undisclosed frozen food supplier.
Why it matters:
Food distribution is a classic ABL sector, and a classic monitoring challenge. Inventory is perishable, seasonal and cold-chain dependent. Receivables concentrate in a handful of large grocery and food service customers with long payment terms.
Key risks:
Inventory eligibility can move quickly with shelf life and cold storage conditions. Customer concentration in receivables creates single-name exposure. Commodity input costs and freight compress margins with little warning.
Opportunities:
For lenders with real inventory analytics, this is exactly the collateral where advance rates can be set with confidence rather than conservatism. The competitive advantage comes from measuring the borrowing base more frequently and more accurately than the next lender.
The specialty tail
Four smaller transactions completed the week, and they matter more than their size suggests.
Utica Equipment Finance wrote a $9.2 million capital lease for a pipe and steel manufacturer. Briar Capital Real Estate Fund provided a $5 million real estate loan to an industrial equipment company. nFusion Capital opened a $5 million factoring facility for a media production company. First Business Bank provided a $1 million factoring facility to a staffing firm.
These are four different collateral types, four different structures and four different monitoring cadences. Factoring requires invoice-level verification. Capital leases require equipment schedules and residual tracking. Owner-occupied real estate lending requires valuation and covenant monitoring. Each is operationally distinct, and each demands the same underlying discipline.
The point is not the aggregate dollars. It is that a diversified specialty credit portfolio is a collection of these, and the operational burden compounds faster than the assets under management.
Takeaways
- Borrowers are unbundling their capital stacks. Hillman separated enterprise debt from collateral debt and priced each with the lender base best suited to it. Expect more issuers to run parallel term and asset-based facilities rather than a single blended structure.
- Non-dilutive credit is competing directly with equity. Kestra’s milestone-linked facility is a growth financing instrument dressed as a term loan. The structure works because the lender is willing to release capital against operating data rather than against collateral.
- Execution speed is a pricing input. Peachtree closed a $150 million hospitality bridge in under 45 days for a fourth-time borrower. Certainty of close, backed by existing performance data, is worth real basis points to sponsors.
- Contractual cash flow is now mainstream collateral. Royalty streams, contracted energy revenue and rental fleet income all cleared bank and specialty balance sheets in a single week. The common requirement is continuous, granular data on the underlying performance.
- Announced capacity is not funded exposure. Undrawn revolvers, accordions, optional tranches and milestone-gated commitments made up a meaningful share of last week’s headline numbers. Portfolio-level reporting that cannot distinguish committed, available and funded amounts will systematically misstate risk.
How Cardo AI helps Asset managers and Lenders
Look across last week’s eleven transactions and the operational requirement is identical at every scale. A $1.1 billion syndicated refinancing and a $1 million factoring line both need the same things done well, continuously, and without a spreadsheet in the critical path.
Cardo AI provides the operating layer for asset-based finance and private credit portfolios, covering the full lifecycle from loan tape ingestion to investor reporting.
- Loan tape ingestion across any source or format. Servicer files, originator extracts, agent reports and bank feeds normalised into a single data model, whatever the asset class.
- Borrowing base, eligibility and waterfall computation. Advance rates, eligibility criteria, reserves and concentration limits calculated automatically and reproducibly, including across multi-currency and multi-jurisdiction collateral pools.
- Covenant, trigger and concentration monitoring. Continuous testing against facility terms, with alerts before a breach becomes a conversation with investors.
- Portfolio analytics and stress testing. Scenario analysis across vintages, sectors, geographies and structures, so that concentration is visible before it becomes correlated.
- Institutional-grade investor reporting. Consistent, auditable reporting packages produced on schedule rather than assembled under pressure.
- Multi-asset-class onboarding. From aviation and rail fleets to skilled nursing portfolios, camera rental equipment to frozen food inventory, new asset classes onboard in weeks rather than quarters.
The lenders who took size last week were, in almost every case, the ones who already held the data. Repeat mandates, faster closings and tighter pricing all traced back to information advantage. That advantage is built, not bought.
If you are scaling an ABF or private credit platform and your operational infrastructure is becoming the constraint on origination, we should talk.
Sources
ABL Advisor deal tables (July 20-24, 2026); company press releases via Business Wire, GlobeNewswire, PR Newswire and Bloomberg; ABF Journal; and issuer investor relations pages.
If you’re scaling an asset-based or private credit book, we should talk.